DDInter624 DDInter1492
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
Efavirenz {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Ponatinib
Efavirenz {u} (Compound) upregulates {v} (Gene) IKBKB
IKBKB {u} (Gene) is upregulated by {v} (Compound) Ponatinib
Efavirenz {u} (Compound) downregulates {v} (Gene) OXA1L
OXA1L {u} (Gene) is downregulated by {v} (Compound) Ponatinib
Efavirenz {u} (Compound) causes {v} (Side Effect) Migraine
Migraine {u} (Side Effect) is caused by {v} (Compound) Ponatinib
Efavirenz {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Nilotinib
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Efavirenz {u} (Compound) upregulates {v} (Gene) IKBKB
IKBKB {u} (Gene) interacts with {v} (Gene) FLT3
FLT3 {u} (Gene) is bound by {v} (Compound) Ponatinib
Efavirenz {u} (Compound) downregulates {v} (Gene) OXA1L
OXA1L {u} (Gene) is regulated by {v} (Gene) RET
RET {u} (Gene) is bound by {v} (Compound) Ponatinib
Efavirenz {u} (Compound) downregulates {v} (Gene) POLR2I
POLR2I {u} (Gene) is downregulated by {v} (Compound) Nilotinib
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Efavirenz {u} (Compound) causes {v} (Side Effect) Migraine
Migraine {u} (Side Effect) is caused by {v} (Compound) Nilotinib
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Efavirenz {u} (Compound) causes {v} (Side Effect) Hot flush
Hot flush {u} (Side Effect) is caused by {v} (Compound) Lansoprazole
Lansoprazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ponatinib
Efavirenz (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Ponatinib (Compound)
Efavirenz (Compound) upregulates IKBKB (Gene) and IKBKB (Gene) is upregulated by Ponatinib (Compound)
Efavirenz (Compound) downregulates OXA1L (Gene) and OXA1L (Gene) is downregulated by Ponatinib (Compound)
Efavirenz (Compound) causes Migraine (Side Effect) and Migraine (Side Effect) is caused by Ponatinib (Compound)
Efavirenz (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Nilotinib (Compound) and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Efavirenz (Compound) upregulates IKBKB (Gene) and IKBKB (Gene) interacts with FLT3 (Gene) and FLT3 (Gene) is bound by Ponatinib (Compound)
Efavirenz (Compound) downregulates OXA1L (Gene) and OXA1L (Gene) is regulated by RET (Gene) and RET (Gene) is bound by Ponatinib (Compound)
Efavirenz (Compound) downregulates POLR2I (Gene) and POLR2I (Gene) is downregulated by Nilotinib (Compound) and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Efavirenz (Compound) causes Migraine (Side Effect) and Migraine (Side Effect) is caused by Nilotinib (Compound) and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Efavirenz (Compound) causes Hot flush (Side Effect) and Hot flush (Side Effect) is caused by Lansoprazole (Compound) and Lansoprazole may cause a minor interaction that can limit clinical effects when taken with Ponatinib